` MNMD (Mind Medicine (MindMed) Inc) vs S&P 500 Comparison - Alpha Spread

MNMD
vs
S&P 500

Over the past 12 months, MNMD has underperformed S&P 500, delivering a return of -4% compared to the S&P 500's 9% growth.

Stocks Performance
MNMD vs S&P 500

Loading
MNMD
S&P 500
Add Stock

Performance Gap
MNMD vs S&P 500

Loading
MNMD
S&P 500
Difference
www.alphaspread.com

Performance By Year
MNMD vs S&P 500

Loading
MNMD
S&P 500
Add Stock

Competitors Performance
Mind Medicine (MindMed) Inc vs Peers

S&P 500
MNMD
LLY
JNJ
NOVO B
ROG
Add Stock

Mind Medicine (MindMed) Inc
Glance View

Economic Moat
None
Market Cap
535.4m USD
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.

MNMD Intrinsic Value
Not Available
Back to Top